In my last article titled “ACADIA: The company perspectives in numbers”, I described the demographic trends that the company is operating under, listed key near-term catalysts, and made an overview of the company’s development. However, in the comments to the article, I noticed investor interest in the company’s valuations and price target. Thus, I decided to perform a valuation of the company’s existing segment for PDP treatment with its marketed medication NUPLAZID, as well as take a look at the 10-year horizon for the company segment under different assumptions and 3 scenarios.
In